



Resolution n° 14-2019-e

Go-ahead for the development of grant agreement packages on Accelerating impact of long-acting technologies in low- and middle-income countries for proposed projects with MedinCell, University of Liverpool, and University of Washington

With reference to the Area for Intervention: **Accelerating impact of long-acting technologies in low- and middle-income countries** as approved by the Executive Board in Resolution EB30/2018/R4; and

Taking into account the project proposal assessments by the Joint Review Committee, the Executive Board authorizes the Secretariat to *go-ahead* with the development into draft grant agreement packages for subsequent submission to and approval by the Board, of the following proposed projects:

1. IMPACT: Long-acting Injectable formulation of Ivermectin as a new vector control tool to reduce malaria transmission (MedinCell)
2. LONGEVITY: LONG acting pipeline to Establish medicines for malaria, tuberculosis and hepatitis C Virus with Infrastructure for sustainable Translational capacity (UoL)
3. Repurposing oral TLD: Repurposing oral tenofovir-lamivudine-dolutegravir (TLD) to a long-acting injectable combination HIV medicine using a novel technology (UoW)

The Board recalls that, in accordance with Resolution EB22/2015/R3, the Secretariat may now use the Project Preparation Facility to support the effective development of the grant agreement packages for these proposals. This decision has no other funding implications.

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 18 July 2019